Pulmonary Perspectives®
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
-
A sticky road: Mucus pathology in COPD
Targeting mucus pathology could fulfill an unmet therapeutic need in managing patients with COPD and provide a novel approach to addressing the underlying mechanisms contributing to airway obstruction.
-
Navigating new ACR/CHEST guidelines for screening, monitoring, and treatment of SARD-ILD
Authors Jose R. Castellanos, MD; Anthony J. Esposito, MD; and Caroline Zhao, MD, discuss key strategies, including early screening with pulmonary function tests and high-resolution chest tomography, cautious glucocorticoid use, and personalized steroid-sparing treatment.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all […]
-
Changing the tumor board conversation: Immunotherapy in resectable NSCLC
Without a doubt, immunotherapy has transformed the treatment landscape of non-small cell lung cancer (NSCLC) and enhanced survival rates across the different stages of disease. High recurrence rates following complete […]
-
Military burn pits: Their evidence and implications for respiratory health
Military service is a hazard-ridden profession. It’s easy to recognize the direct dangers from warfighting, such as gunfire and explosions, but the risks from environmental, chemical, and other occupational exposures […]
-
Managing severe asthma exacerbations in the ED: We need answers beyond albuterol
Evidence-based medicine (EBM) stems from making the best patient-centered decision from the highest-quality data available that comports with our understanding of pathophysiology. In some situations, clinicians are forced to draw […]
-
Obesity and lung disease in the era of GLP-1 agonists
Now is the time for pulmonary clinicians to become comfortable counseling patients about and treating obesity. By 2030, half of the US population will have obesity, a quarter of which […]
-
The double-edged sword of virtual pulmonary rehabilitation
Pulmonary rehabilitation (PR) is an invaluable program typically set in structured in-person environments for individuals living with chronic respiratory conditions. It offers a comprehensive approach to improving lung health and […]
-
Home oxygen therapy: What does the data show?
Inhalers, nebulizers, antibiotics, and steroids – these are some of the most common tools in our pulmonary arsenal that we deploy on a daily basis. But, there is no treatment […]
